Advanced SearchSearch Tips
Potential Benefit of Metformin as Treatment for Colon Cancer: the Evidence so Far
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Potential Benefit of Metformin as Treatment for Colon Cancer: the Evidence so Far
Abdelsatir, Azza Ali; Husain, Nazik Elmalaika; Hassan, Abdallah Tarig; Elmadhoun, Wadie M; Almobarak, Ahmed O; Ahmed, Mohamed H;
  PDF(new window)
Metformin is known as a hypoglycaemic agent that regulates glucose homeostasis by inhibiting liver glucose production and increasing muscle glucose uptake. Colorectal cancer (CRC) is one of the most common cancers worldwide, with about a million new cases diagnosed each year. The risk factors for CRC include advanced age, smoking, black race, obesity, low fibre diet, insulin resistance, and the metabolic syndrome. We have searched Medline for the metabolic syndrome and its relation to CRC, and metformin as a potential treatment of colorectal cancer. Administration of metformin alone or in combination with chemotherapy has been shown to suppress CRC. The mechanism that explains how insulin resistance is associated with CRC is complex and not fully understood. In this review we have summarised studies which showed an association with the metabolic syndrome as well as studies which tackled metformin as a potential treatment of CRC. In addition, we have also provided a summary of how metformin at the cellular level can induce changes that suppress the activity of cancer cells.
Metformin;colon cancer;obesity and insulin resistance;
 Cited by
Metformin augments doxorubicin cytotoxicity in mammary carcinoma through activation of adenosine monophosphate protein kinase pathway, Tumor Biology, 2017, 39, 5, 101042831769223  crossref(new windwow)
Aleksandrova K, Boeing H, Jenab M, et al (2011). Metabolic syndrome and risks of colon and rectal cancer: the European prospective investigation into cancer and nutrition study. Cancer Prev Res, 4, 1873-83. crossref(new window)

Buzzai M, Jones R, Amaravadi R, et al (2007). Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res, 67, 6745-52. crossref(new window)

Cho Y, Ko B, Kim S, et al (2014). Does metformin affect the incidence of colonic polyps and adenomas in patients with type 2 diabetes mellitus? Intest Res, 12, 139-45. crossref(new window)

Donohoe C, O'farrell N, Doyle S, Reynolds J (2014). The role of obesity in gastrointestinal cancer: evidence and opinion. Therap Adv Gastroenterol, 7, 38-50. crossref(new window)

Giovannucci E, Pollak M, Platz E, et al (2000). A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev, 9, 345-9.

Grimberg A & Cohen P (2000). Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol, 183, 1-9. crossref(new window)

Handelsman Y, Leroith D, Bloomgarden Z, et al (2013). Diabetes and cancer--an AACE/ACE consensus statement. Endocr Pract, 19, 675-93. crossref(new window)

Higurashi T, Takahashi H, Endo H, et al (2012). Metformin efficacy and safety for colorectal polyps: a double-blind randomized controlled trial. BMC Cancer, 12, 118. crossref(new window)

Hillon P, Guiu B, Vincent J, Petit J (2010). Obesity, type 2 diabetes and risk of digestive cancer. Gastroenterol Clin Biol, 34, 529-33. crossref(new window)

Hsu Y, Chiu H, Liou J, et al (2012). Glycated hemoglobin A1c is superior to fasting plasma glucose as an independent risk factor for colorectal neoplasia. Cancer Causes Control, 23, 321-8. crossref(new window)

Huang HE, Yang YC, Wu JS, et al (2014). The relationship between different glycemic statuses and colon polyps in a Taiwanese population. J Gastroenterol, 49, 1145-51. crossref(new window)

Inoue M, Tsugane S (2012). Insulin resistance and cancer: epidemiological evidence. Endocr Relat Cancer, 19, F1-8. crossref(new window)

Jenkins P (2004). Acromegaly and cancer. Horm Res, 62, 108-15. crossref(new window)

Kalaany N, Sabatini D (2009). Tumours with PI3K activation are resistant to dietary restriction. Nature, 458, 725-31. crossref(new window)

Kanadiya M, Gohel T, Sanaka M, Thota P, Shubrook J (2013). Relationship between type-2 diabetes and use of metformin with risk of colorectal adenoma in an American population receiving colonoscopy. J Diabetes Complications, 27, 463-6. crossref(new window)

Kaneko R, Nakazaki N, Tagawa T, et al (2014) A new index of abdominal obesity which effectively predicts risk of colon tumor development in female Japanese. Asian Pac J Cancer Prev, 15, 1005-10. crossref(new window)

Khaw K, Wareham N, Bingham S, et al (2004). Preliminary communication: glycated hemoglobin, diabetes, and incident colorectal cancer in men and women: a prospective analysis from the European prospective investigation into cancer-Norfolk study. Cancer Epidemiol Biomarkers Prev, 13, 915-9.

Kim D (2012). [Obesity and gastrointestinal cancer-related factor]. Korean J Gastroenterol, 59, 8-15. crossref(new window)

Larsson S, Wolk A (2007). Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. Am J Clin Nutr, 86, 556-65. crossref(new window)

Lee D, Kim B, Lee J, et al (2012). The effect of metformin on responses to chemotherapy and survival in stage IV colorectal cancer with diabetes. Korean J Gastroenterol, 60, 355-61. crossref(new window)

Lega I, Shah P, Margel D, et al (2014). The effect of metformin on mortality following cancer among patients with diabetes. Cancer Epidemiol Biomarkers Prev, 23, 1974-84. crossref(new window)

Li W, Wang Q, Liu X, et al (2015). Combined use of vitamin D3 and metformin exhibits synergistic chemopreventive effects on colorectal neoplasia in rats and mice. Cancer Prev Res, 8, 139-48. crossref(new window)

Mahmood K, Naeem M & Rahimnajjad N (2013). Metformin: the hidden chronicles of a magic drug. Eur J Intern Med, 24, 20-6. crossref(new window)

Mei Z, Zhang Z, Liu C, et al (2014). Survival benefits of metformin for colorectal cancer patients with diabetes: a systematic review and meta-analysis. PLoS One, 9, 91818. crossref(new window)

Mulholland H, Murray L, Cardwell C & Cantwell M (2009). Glycemic index, glycemic load, and risk of digestive tract neoplasms: a systematic review and meta-analysis. Am J Clin Nutr, 89, 568-76. crossref(new window)

Na S & Myung S (2012). [Obesity and colorectal cancer]. Korean J Gastroenterol, 59, 16-26. crossref(new window)

Ogden C, Carroll M, Curtin L, et al (2006). Prevalence of overweight and obesity in the United States, 1999-2004. JAMA, 295, 1549-55. crossref(new window)

Pais R, Silaghi H, Silaghi A, Rusu M & Dumitrascu D (2009). Metabolic syndrome and risk of subsequent colorectal cancer. World J Gastroenterol, 15, 5141-8. crossref(new window)

Rampal S, Yang MH, Sung J, et al (2014). Association between markers of glucose metabolism and risk of colorectal adenoma. Gastroenterol, 147, 78-87. crossref(new window)

Renehan A, Roberts D, Dive C (2008). Obesity and cancer: pathophysiological and biological mechanisms. Arch Physiol Biochem, 114, 71-83. crossref(new window)

Sanchez N, Stierman B, Saab S, et al (2012). Physical activity reduces risk for colon polyps in a multiethnic colorectal cancer screening population. BMC Res Notes, 5, 312. crossref(new window)

Sandhu M, Dunger D, Giovannucci E (2002). Insulin, insulinlike growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst, 94, 972-80. crossref(new window)

Saydah SH, Platz EA, Rifai N, et al (2003). Association of markers of insulin and glucose control with subsequent colorectal cancer risk. Cancer Epidemiol Biomarkers Prev, 12, 412-8.

Schoenalgire C, Amrein L, Zakikhani M, Panasci L & Pollak M (2010). Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocr Relat Cancer, 17, 351-60. crossref(new window)

Spillane S, Bennett K, Sharp L, Barron T (2014). Metformin exposure and disseminated disease in patients with colorectal cancer. Cancer Epidemiol, 38, 79-84. crossref(new window)

Sui X, Xu Y, Yang J, et al (2014). Use of metformin alone is not associated with survival outcomes of colorectal cancer cell but AMPK activator AICAR sensitizes anticancer effect of 5-fluorouracil through AMPK activation. PLoS One, 9, 97781. crossref(new window)

Trevisan M, Liu J, Muti P, et al (2001). Markers of insulin resistance and colorectal cancer mortality. Cancer Epidemiol Biomarkers Prev, 10, 937-41.

Tsilidis K, Capothanassi D, Allen N, et al (2014). Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-totreat trial. Diabetes Care, 37, 2522-32. crossref(new window)

Vu HT, Ufere N, Yan Y, et al (2014). Diabetes mellitus increases risk for colorectal adenomas in younger patients. World J Gastroenterol, 20, 6946-52. crossref(new window)

Wang X, Zhang Y (2014). Targeting mTOR network in colorectal cancer therapy. World J Gastroenterol, 20, 4178-88. crossref(new window)

Warren R, Yuan H, Matli M, Ferrara N, Donner D (1996). Induction of vascular endothelial growth factor by insulinlike growth factor 1 in colorectal carcinoma. J Biol Chem, 271, 29483-8. crossref(new window)

Williams A, Collard T, Perks C, et al (2000). Increased p53- dependent apoptosis by the insulin-like growth factor binding protein IGFBP-3 in human colonic adenoma-derived cells. Cancer Res, 60, 22-7.

Yun K, Chang Y, Jung H, et al (2013). Impact of body mass index on the risk of colorectal adenoma in a metabolically healthy population. Cancer Res, 73, 4020-7. crossref(new window)

Zaafar D, Zaitone S & Moustafa Y (2014). Role of metformin in suppressing 1,2-dimethylhydrazine-induced colon cancer in diabetic and non-diabetic mice: effect on tumor angiogenesis and cell proliferation. PLoS One, 9, 100562. crossref(new window)

Zaninotto P, Pierce M, Breeze E, De Oliveira C, Kumari M (2010). BMI and waist circumference as predictors of wellbeing in older adults: findings from the english longitudinal study of ageing. Obesity, 18, 1981-7. crossref(new window)

Zhang P, Li H, Tan X, Chen L, Wang S (2013a). Association of metformin use with cancer incidence and mortality: a metaanalysis. Cancer Epidemiol, 37, 207-18. crossref(new window)

Zhang Y, Guan M, Zheng Z, et al (2013b). Effects of metformin on CD133+ colorectal cancer cells in diabetic patients. PLoS